Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2016 April;107(2) > Minerva Medica 2016 April;107(2):77-83

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669

 

Minerva Medica 2016 April;107(2):77-83

    REVIEWS

Long noncoding RNA ANRIL: a potential novel prognostic marker in cancer: a meta-analysis

Fang T. LIU, Pei Q. ZHU, Hong L. LUO, Yi ZHANG, Teng F. HAO, Guang F. XIA, Zheng M. ZHU, Cheng QIU

Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China

INTRODUCTION: Numerous researches have showed that the dysregulation of lncRNA ANRIL play a significant role in cancer progression, and high expression of ANRIL may have important clinical value. This meta-analysis aims to investigate potential clinical application role of ANRIL as a biomarker for cancer prognosis.
EVIDENCE ACQUISTION: The electronic search was conducted in Pubmed, EMBASE, Web of Science, CNKI and Wanfang database (up to January 27, 2016). We collected relevant articles to explore the association between the expression levels of ANRIL and overall survival (OS).
EVIDENCE SYNTHESIS: A total of 519 cancer patients from six studies were finally included. The results showed that cancer patients with high ANRIL expression may have a poorer OS (HR=1.95, 95%CI:1.37-2.53, P=0.000, fixed-effect model) than those with low ANRIL expression.
CONCLUSIONS: High expression of ANRIL is associated with poor clinical outcome. ANRIL might be act as a novel potential prognostic biomarker in various cancers.

language: English


FULL TEXT  REPRINTS

top of page